card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services

Learn more
English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search

Insight

A Next Generation Sequencing Approach to Influenza Vaccine Development

NGS approach to strain identification and genomic characterization of influenza
Home / Insights / A Next Generation Sequencing Approach to Influenza Vaccine Development

Influenza typing/identification is enabled by serological tests as well as genotyping of discrete regions of the viral genome. In contrast to Sanger sequencing, Next Generation Sequencing (NGS) provides a streamlined, high-throughput approach to strain identification and broader genomic characterization of influenza, including viral evolution in the wild or in response to vaccine or antiviral challenges.

We can use that sequence information to inform future development of vaccines and therapeutics. NGS presents new possibilities for influenza vaccine development. In this white paper, you will explore the challenges of developing influenza vaccines and new approaches that may eventually lead to a more universal solution.

Complete the form below to access this white paper